Pharmacokinetic and pharmacodynamic study on amrubicin and amrubicinol in Japanese patients with lung cancer-Reference-Cited by-同舟云学术

Pharmacokinetic and pharmacodynamic study on amrubicin and amrubicinol in Japanese patients with lung cancer

Published:2011-11-01 Issue:4 Volume:69 Page:861-869
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Makino Yoshinori,Yamamoto Noboru,Sato Hitoshi,Ando Reiko,Goto Yasushi,Tanai Chiharu,Asahina Hajime,Nokihara Hiroshi,Sekine Ikuo,Kunitoh Hideo,Ohe Yuichiro,Sugiyama Erika,Yokote Nobuaki,Tamura Tomohide,Yamamoto Hiroshi

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s00280-011-1768-8.pdf

Reference18 articles.

1. Hanada M, Mizuno S, Fukushima A, Saito Y, Noguchi T, Yamaoka T (1998) A new antitumor agent amrubicin induces cell growth inhibition by stabilizing topoisomerase II-DNA complex. Jpn J Cancer Res 89:1229–1238

2. Onoda S, Masuda N, Seto T, Eguchi K, Takiguchi Y, Isobe H, Okamoto H, Ogura T, Yokoyama A, Seki N, Asaka-Amano Y, Harada M, Tagawa A, Kunikane H, Yokoba M, Uematsu K, Kuriyama T, Kuroiwa Y, Watanabe K (2006) Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301. J Clin Oncol 24:5448–5453

3. Kato T, Nokihara H, Ohe Y, Yamamoto N, Sekine I, Kunitoh H, Kubota K, Nishiwaki Y, Saijo N, Tamura T (2006) Phase II trial of amrubicin in patients with previously treated small cell lung cancer (SCLC) J Clin Oncol, ASCO Annual Meeting Proceedings Part I, (18S):7061

4. Inoue A, Sugawara S, Yamazaki K, Maemondo M, Suzuki T, Gomi K, Takanashi S, Inoue C, Inage M, Yokouchi H, Watanabe H, Tsukamoto T, Saijo Y, Ishimoto O, Hommura F, Nukiwa T (2008) Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402. J Clin Oncol 26:5401–5406

5. Kaira K, Sunaga N, Tomizawa Y, Yanagitani N, Shimizu K, Imai H, Utsugi M, Iwasaki Y, Iijima H, Tsurumaki H, Yoshii A, Fueki N, Hisada T, Ishizuka T, Saito R, Mori M (2010) A phase II study of amrubicin, a synthetic 9-aminoanthracycline, in patients with previously treated lung cancer. Lung Cancer 69:99–104

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Individual optimal dose of amrubicin to prevent severe neutropenia in Japanese patients with lung cancer;Cancer Science;2019-10-03

2. Simultaneous optimization of limited sampling points for pharmacokinetic analysis of amrubicin and amrubicinol in cancer patients;Asia-Pacific Journal of Clinical Oncology;2016-03-07

3. Amrubicin hydrochloride for relapsed small-cell lung cancer;Expert Opinion on Orphan Drugs;2013-11-07

4. Amrubicin: potential in combination with cisplatin or carboplatin to treat small-cell lung cancer;Drug Design, Development and Therapy;2013-08

5. The role of anthracyclines in small cell lung cancer;ANN TRANSL MED;2013